Prescription drug savings from Abbvie

Prescription drugs play a crucial role in improving the health and well-being of individuals. However, the high cost of medications can be a significant barrier for many patients to access the treatments they need. AbbVie, a leading pharmaceutical company, understands the importance of ensuring patients can afford and access the medicines prescribed to them. In this article, we will explore the various patient assistance and support programs offered by AbbVie.

AbbVie’s Patient Assistance Programs

AbbVie’s patient assistance programs are designed to provide free AbbVie medicines to qualifying patients who reside in the United States and have limited or no health insurance coverage. These programs are aimed at individuals who demonstrate a qualifying financial need. In 2022 alone, AbbVie assisted nearly 200,000 people through these programs, ensuring that they could receive the medications they require without the burden of high costs.

Eligibility Criteria for myAbbVie Assist

To be eligible for AbbVie’s myAbbVie Assist program, patients must meet certain criteria:

• Patients must be receiving treatment from a licensed U.S. healthcare provider on an outpatient basis and be prescribed an AbbVie medicine that is included in the assistance program
• Patients should have limited or no health insurance coverage. The program aims to support individuals who face financial difficulties accessing necessary medications due to insufficient insurance coverage
• Patients must demonstrate a qualifying financial need. AbbVie has specific income criteria that determine eligibility for their assistance programs, ensuring that those who genuinely require financial support receive it
• The myAbbVie Assist program is available to individuals who reside in the United States

It is important to note that patients with commercial insurance plans that require them to apply for myAbbVie Assist as a condition for coverage are not eligible for the program.

How to Enroll in myAbbVie Assist

Enrolling in AbbVie’s myAbbVie Assist program is a simple process. Follow these steps to apply for and receive your medication:

• Visit AbbVie’s website and access the list of AbbVie treatments that are eligible for myAbbVie Assist. Review the eligibility information to ensure that your prescribed medication is included
• If you meet the eligibility criteria, complete the provided application form in collaboration with your healthcare provider. Make sure to provide accurate information to avoid any delays in the process
• AbbVie aims to review your application within two days of submission. During this time, they will assess your eligibility based on the criteria mentioned earlier. You and your healthcare provider will be updated on the status of your application
• If you have any questions or need assistance during the application process, you can reach out to AbbVie’s dedicated helpline at 1-800-222-6885. Their team is there to support you and provide guidance

Access to a wide range of medications

The available medicines are listed below, if you are eligible for AbbVie’s myAbbVie Assist program:

• ALLODERM™ Regenerative Tissue Matrix
• Alphagan® P (brimonidine tartrate) ophthalmic solution
• Armour Thyroid® (thyroid tablets, USP) tablets
• Avycaz® (avibactam, ceftazidime) powder
• BOTOX® (onabotulinumtoxinA)
• Canasa® (mesalamine) suppository
• CREON® (pancrelipase) Delayed-Release Capsules
• Crinone® (progesterone) gel
• Dalvance® (dalbavancin) lyophilisate
• Delzicol® (mesalamine DR) capsules
• Depakote® (divalproex sodium)
• DUOPA (carbidopa and levodopa) enteral suspension
• Durysta® (bimatoprost) ocular implant
• Fetzima® (levomilnacipran) Extended Release Capsules and Titration Pack
• GENGRAF®Capsules (cyclosporine capsules, USP [MODIFIED])
• HUMIRA® (adalimumab)
• IMBRUVICA® (ibrutinib)
• KALETRA® (lopinavir/ritonavir) Tablets
• KELLER FUNNEL® 2
• Linzess® (linaclotide) capsules
• Lumigan® (bimatoprost 0.01%) opthalmic solution
• LUPRON DEPOT® (leuprolide acetate for depot suspension)
• LUPRON DEPOT-PED® (leuprolide acetate for depot suspension)
• MAVYRET® (glecaprevir/pibrentasvir)
• Namzaric® (memantine HCl extended-release and donepezil HCl) capsule
• NATRELLE®
• NORVIR® (ritonavir) tablets and oral solution
• Oriahnn™ (elagolix/estradiol/norethindrone acetate)
• ORILISSA™ (elagolix) tablets
• Ozurdex® (dexamethasone) ocular implant
• QULIPTA™ (atogepant) tablets
• Rectiv® (nitroglycerin) ointment
• Restasis® (cyclosporine) ophthalmic emulsion
• REVOLVE™ System Advanced Adipose System
• RINVOQ™ (upadacitinib)
• Saphris® (asenapine maleate) sublingual tablet
• Savella® (milnacipran HCl) tablets
• SKYRIZI™ (risankizumab-rzaa)
• STRATTICE™ and STRATTICE™ BPS Reconstructive Tissue Matrix
• Synthroid® (levothyroxine sodium) tablets
• Teflaro® (ceftaroline fosamil) powder for injection
• Ubrelvy® (ubrogepant) tablets
• VENCLEXTA™ (venetoclax tablets)
• Viberzi® (eluxadoline) tablets
• Viibryd® (vilazodone HCl) tablets
• Vraylar® (cariprazine) capsules
• Xen® Gel Stent

AbbVie Prescription Savings Programs

AbbVie has established various prescription savings cards to assist eligible patients in reducing their out-of-pocket costs. These programs are designed to complement existing insurance coverage and provide significant savings on specific medications:

• Alphagan® P (brimonidine tartrate) ophthalmic solution
  
• BOTOX® (onabotulinumtoxinA)
  
• Bystolic® (nebivolol) tablets
  
• Combigan® (brimonidine tartrate/timolol maleate) opthalmic solution
  
• Creon® (pancrelipase) Delayed-Release Capsules)
  
• Crinone® (progesterone) gel
  
• Dalvance® (dalbavancin) lyophilisate
  
• Delzicol® (mesalamine DR) capsules
  
• Depakote
  
• Duopa
  
• Durysta® (bimatoprost) ocular implant
  
• Fetzima® (levomilnacipran) Extended Release Capsules and Titration Pack
  
• HUMIRA® (adalimumab)
  
• IMBRUVICA® (ibrutinib)
  
• Kaletra 
  
• Lo Loestrin® Fe
  
• Linzess® (linaclotide) capsules
  
• Lumigan® (bimatoprost 0.01%) opthalmic solution
  
• Lupron
  
• MAVYRET® (glecaprevir/pibrentasvir)
  
• Namzaric® (memantine HCl extended-release and donepezil HCl) capsule
  
• Norvir
  
• Oriahann
  
• Orilissa
  
• Ozurdex® (dexamethasone) ocular implant
  
• Pred Forte® (prednisolone acetate) ophthalmic suspension
  
• QULIPTATM (atogepant) tablets
  
• Restasis® (cyclosporine) ophthalmic emulsion
  
• RINVOQ™ (upadacitinib)
  
• Saphris® (asenapine maleate) sublingual tablet
  
• Savella® (milnacipran HCl) tablets
  
• SKYRIZI™ (risankizumab-rzaa)
  
• Synthroid® (levothyroxine sodium) tablets
  
• Ubrelvy® (ubrogepant) tablets
  
• VENCLEXTA™ (venetoclax tablets)
  
• Viberzi® (eluxadoline) tablets
  
• Viibryd® (vilazodone HCl) tablets
  
• Vraylar® (cariprazine) capsules

Conclusion

In conclusion, AbbVie’s patient assistance programs, particularly myAbbVie Assist, offer a lifeline to patients struggling with the high costs of prescription medications. By simplifying the application process and providing free AbbVie medicines to those who qualify, AbbVie is ensuring that patients receive the treatments they need without financial constraints. If you or someone you know meets the eligibility criteria, don’t hesitate to explore the options available through AbbVie’s patient assistance programs. Take the first step towards affordable and accessible medications today. Visit AbbVie website for more information.

Sources

• AbbVie website